Direct Amplification Of Research Samples Associated With Upper Respiratory Infections

This content is brought to you by Integrated DNA Technologies, a Danaher Operating Company.
Faster pathogen detection is becoming essential as labs balance throughput, cost, and accuracy. Direct amplification workflows offer a streamlined alternative to traditional extraction-based qPCR, enabling researchers to move from sample to result with fewer steps and lower per-sample costs. By eliminating nucleic acid extraction, workflows can cut processing time by up to two hours while maintaining reliable detection across targets like influenza A, influenza B, and SARS-CoV-2.
Performance data highlight the role of amplification enhancers in overcoming PCR inhibitors commonly found in saliva and nasopharyngeal samples, delivering a stronger signal and improved consistency. In some cases, direct amplification even matches or exceeds extracted sample performance, suggesting a practical path to simplifying respiratory research workflows without compromising sensitivity.
Discover how adopting extraction-free approaches can help accelerate your lab’s productivity while managing costs.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.